Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP & CFO | November 25, 2019 | November 25, 2019 |
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | February 04, 2026 | February 05, 2026 |
| HP INCHPQ · Entity 642 | Director | April 16, 2026 | April 20, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Financial Officer | August 09, 2022 | August 11, 2022 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 18, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date November 25, 2019 · Filed November 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,378 |
Reported balance
After 2019-11-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-11-25 · Sale · Disposed 8,737 · Balance 49,378 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,523 RSUs which vest in one installment on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022; and 4,511 which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2: These shares include 637 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,523 RSUs which vest in one installment on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022; and 4,511 which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These shares include 637 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Eikon Therapeutics, Inc.
Report date February 04, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.12 · Expires 2035-11-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-02-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares underlying the option will vest in equal monthly installments for four years after the vesting starting date, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in equal monthly installments for four years after the vesting starting date, subject to the Reporting Person's continued service through each date.
HP INC
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,176 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 12,176 · Balance 12,176 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of HP common stock. F2: On 04/16/2026, the reporting person was granted 12,176 RSUs, all of which vested on the grant date. F3: The reporting person elected to defer the receipt of common stock until 04/01/2033. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of HP common stock.
F2: On 04/16/2026, the reporting person was granted 12,176 RSUs, all of which vested on the grant date.
F3: The reporting person elected to defer the receipt of common stock until 04/01/2033.
Moderna, Inc.
Report date August 09, 2022 · Filed August 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,021 |
Reported balance
After 2022-08-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-08-09 · Exercise / conversion · Acquired 348 · Balance 3,021 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: Includes 90 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 2,857 |
Reported balance
After 2022-08-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-08-10 · Sale · Disposed 164 · Balance 2,857 F3: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,482 |
Reported balance
After 2022-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-09 · Exercise / conversion · Disposed 348 · Balance 3,482 F1: Restricted stock units convert into common stock on a one-for-one basis. F4: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Includes 90 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.
F3: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 18, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,116 |
Reported balance
After 2024-06-18 transaction · row 1
1 source rowRow 1 · 2024-06-18 · Grant · Acquired 17,116 · Balance 57,116 F1: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest on the one (1) year anniversary of the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2034-06-18 | Direct | 24,134 |
Reported balance
After 2024-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-18 · Grant · Acquired 24,134 · Balance 24,134 F2: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest on the one (1) year anniversary of the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
F2: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:43 UTC | HP INC HPQ · Entity 642 | GrantRestricted Stock Units · Derivative | 12,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001444612-26-000002 · form4-04202026_090436.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,176 Underlying: Common Stock · 12,176 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of HP common stock. F2 · price: On 04/16/2026, the reporting person was granted 12,176 RSUs, all of which vested on the grant date. F2 · derivative.exercise_date: On 04/16/2026, the reporting person was granted 12,176 RSUs, all of which vested on the grant date. F3 · derivative.exercise_date: The reporting person elected to defer the receipt of common stock until 04/01/2033. F2 · derivative.expiration_date: On 04/16/2026, the reporting person was granted 12,176 RSUs, all of which vested on the grant date. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 21:05 UTC | HP INC HPQ · Entity 642 | GrantRestricted Stock Units · Derivative | 9,568 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-054843 · ownership.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,568 Underlying: Common Stock · 9,568 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of HP common stock. F2 · shares: On 04/14/2025, the reporting person was granted 9,568 RSUs, all of which vested on the grant date. F2 · price: On 04/14/2025, the reporting person was granted 9,568 RSUs, all of which vested on the grant date. F2 · derivative.exercise_date: On 04/14/2025, the reporting person was granted 9,568 RSUs, all of which vested on the grant date. F3 · derivative.exercise_date: The reporting person elected to defer the receipt of common stock until 04/01/2032. F2 · derivative.expiration_date: On 04/14/2025, the reporting person was granted 9,568 RSUs, all of which vested on the grant date. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:56 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 24,134 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001299130-24-000151 · wk-form4_1718916984.xml · derivative · entry 2 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,134 Underlying: Common Stock · 24,134 shares Expires 2034-06-18 F2 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:56 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 17,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-24-000151 · wk-form4_1718916984.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,116 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest on the one (1) year anniversary of the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 21:01 UTC | HP INC HPQ · Entity 642 | GrantCommon Stock | 7,943 | $0.00 | $0.00 |
DisclosureSEC source: 0000950172-24-000228 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,690 F1 · shares: On April 22, 2024, the reporting person was granted 7,943 restricted stock units, all of which vested on the grant date. Read SEC document |
| March 06, 2024 Filed Mar 6, 2024 22:36 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | PurchaseCommon Stock | 40,000 | $4.40 | $176,160.00 |
DisclosureSEC source: 0001299130-24-000076 · wk-form4_1709764557.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · price: This purchase price represents the weighted average purchase price of the shares acquired ranging from $4.38 to $4.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:17 UTC | HP INC HPQ · Entity 642 | GrantCommon Stock | 2,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054388 · doc4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,747 F1 · shares: On November 1, 2023, the reporting person was granted 2,747 restricted stock units, all of which vested on the grant date. This grant reflects pro-rated annual equity retainer for his first partial year of service as a member of HP's Board of Directors. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 12:15 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 86,954 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001299130-23-000124 · wk-form4_1697458523.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,954 Underlying: Common Stock · 86,954 shares Expires 2033-10-13 F1 · derivative.exercise_date: Mr. Meline was elected to the Board of Directors on October 13, 2023. One-third of the shares subject to the option will vest on the one year anniversary of Mr. Meline joining the Board, and the remainder will vest in equal monthly installments thereafter for 24 months on the same date of the month as his initial start date, provided he continues to serve as a director through each vesting date. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 20:52 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 164 | $173.66 | $28,480.67 |
DisclosureSEC source: 0001127602-22-020829 · form4.xml · nonDerivative · entry 2 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 348 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020829 · form4.xml · derivative · entry 3 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,482 Underlying: Common Stock · 348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 348 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020829 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 90 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 10, 2022 Filed May 11, 2022 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 156 | $133.71 | $20,859.35 |
DisclosureSEC source: 0001127602-22-014148 · form4.xml · nonDerivative · entry 2 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,583 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 348 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014148 · form4.xml · derivative · entry 3 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,830 Underlying: Common Stock · 348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 348 | $134.40 | $46,771.20 |
DisclosureSEC source: 0001127602-22-014148 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:58 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 6,415 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008037 · form4.xml · derivative · entry 2 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,415 Underlying: Common Stock · 6,415 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:58 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 26,020 | $0.00 Strike: $149.52 | $0.00 |
DisclosureSEC source: 0001127602-22-008037 · form4.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,020 Underlying: Common Stock · 26,020 shares Expires 2032-03-01 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:33 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 619 | $158.89 | $98,354.15 |
DisclosureSEC source: 0001127602-22-004566 · form4.xml · nonDerivative · entry 2 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,391 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004566 · form4.xml · derivative · entry 3 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,178 Underlying: Common Stock · 1,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004566 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 118 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:23 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 5,570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005296 · form4.xml · derivative · entry 2 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,570 Underlying: Common Stock · 5,570 shares Expires not disclosed F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:23 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 25,618 | $0.00 Strike: $179.52 | $0.00 |
DisclosureSEC source: 0001127602-21-005296 · form4.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,618 Underlying: Common Stock · 25,618 shares Expires 2031-02-09 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 06, 2020 Filed Jan 11, 2021 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 271,303 | $0.00 Strike: $59.15 | $0.00 |
DisclosureSEC source: 0001127602-21-001413 · form4.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,303 Underlying: Common Stock · 271,303 shares Expires 2030-07-06 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on July 6, 2021 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| November 25, 2019 Filed Nov 25, 2019 23:27 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 8,737 | $234.36 | $2,047,603.32 |
DisclosureSEC source: 0001127602-19-033709 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,378 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,523 RSUs which vest in one installment on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022; and 4,511 which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 637 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:00 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 39,382 | $0.00 Strike: $177.31 | $0.00 |
DisclosureSEC source: 0001127602-19-017650 · form4.xml · derivative · entry 3 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,382 Underlying: Common Stock · 39,382 shares Expires 2029-05-03 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:00 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017650 · form4.xml · nonDerivative · entry 2 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,903 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,523 RSUs which vest on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022; and 4,511 which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 425 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:00 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 795 | $176.50 | $140,317.50 |
DisclosureSEC source: 0001127602-19-017650 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,392 Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:49 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 746 | $179.32 | $133,775.11 |
DisclosureSEC source: 0001127602-19-017343 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,187 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 550 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 22, 2019 Filed Mar 25, 2019 23:36 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 8,040 | $191.89 | $1,542,795.60 |
DisclosureSEC source: 0001127602-19-013162 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,933 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 631 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2019 Filed Mar 9, 2019 00:40 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 16,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-010656 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,746 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 533 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 528 | $192.11 | $101,434.08 |
DisclosureSEC source: 0001127602-19-003508 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,660 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 533 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 28, 2018 Filed Jan 15, 2019 01:44 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001941 · form5.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,188 F1 · shares: The transaction reported involved a gift by the reporting person of shares of the Company's common stock to a charitable donor advised fund. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,340 RSUs which vest in one installment on 1/30/2019; 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 674 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 22:36 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7,382 | $196.55 | $1,450,932.10 |
DisclosureSEC source: 0001127602-18-024508 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,202 F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 1,340 RSUs which vest in one installment on 1/30/2019; 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 488 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2018 Filed May 7, 2018 23:06 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 773 | $169.43 | $130,969.39 |
DisclosureSEC source: 0001127602-18-016537 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,382 F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 1,340 RSUs which vest in one installment on 1/30/2019; 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,633 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:15 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 34,702 | $0.00 Strike: $177.46 | $0.00 |
DisclosureSEC source: 0001127602-18-015841 · form4.xml · derivative · entry 2 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,702 Underlying: Common Stock · 34,702 shares Expires 2028-04-27 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. Read SEC document |
| April 27, 2018 Filed May 1, 2018 23:15 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015841 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,155 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 1,340 RSUs which vest in one installment on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,712 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 23:44 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7,549 | $176.08 | $1,329,227.92 |
DisclosureSEC source: 0001127602-18-012859 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,647 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 1,340 RSUs which vest in one installment on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,712 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:30 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 15,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011022 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,913 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 1,340 RSUs which vest in one installment on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,535 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 01:34 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 496 | $198.00 | $98,208.00 |
DisclosureSEC source: 0001127602-18-003051 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,795 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 1,340 RSUs which vest in one installment on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,535 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 00:50 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7,562 | $174.51 | $1,319,644.62 |
DisclosureSEC source: 0001127602-17-024641 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,920 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 2,640 RSUs which vest in one installment of 1,300 on 1/30/2018 and one installment of 1/340 on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,261 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:55 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 38,126 | $0.00 Strike: $162.60 | $0.00 |
DisclosureSEC source: 0001127602-17-016755 · form4.xml · derivative · entry 2 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,126 Underlying: Common Stock · 38,126 shares Expires 2027-05-01 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. Read SEC document |
| May 01, 2017 Filed May 4, 2017 00:55 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016755 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,227 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 27,081 RSUs which vest in one installment of 13,540 on 8/1/2017 and one installment of 13,541 on 8/1/2018; 2,640 RSUs which vest in one installment of 1,300 on 1/30/2018 and one installment of 1/340 on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,995 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 00:21 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 529 | $157.16 | $83,137.64 |
DisclosureSEC source: 0001127602-17-003208 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,690 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 27,081 RSUs which vest in one installment of 13,540 on 8/1/2017 and one installment of 13,541 on 8/1/2018; 2,640 RSUs which vest in one installment of 1,300 on 1/30/2018 and one installment of 1/340 on 1/30/2019; and 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,723 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 01, 2016 Filed Aug 4, 2016 00:22 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 6,766 | $172.03 | $1,163,954.98 |
DisclosureSEC source: 0001127602-16-059444 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,741 F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 27,081 RSUs which vest in one installment of 13,540 on 8/1/2017 and one installment of 13,541 on 8/1/2018; 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1/340 on 1/30/2019; and 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,306 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:34 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 38,112 | $0.00 Strike: $156.35 | $0.00 |
DisclosureSEC source: 0001127602-16-051293 · form4.xml · derivative · entry 2 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,112 Underlying: Common Stock · 38,112 shares Expires 2026-05-03 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. Read SEC document |
| May 03, 2016 Filed May 6, 2016 00:34 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-051293 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,186 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 40,621 RSUs which vest in two equal installments of 13,540 on 8/1/2016 and 8/1/2017 and one installment of 13,541 on 8/1/2018; 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1/340 on 1/30/2019; and 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,557 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 01, 2015 Filed Aug 4, 2015 22:41 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7,196 | $176.59 | $1,270,741.64 |
DisclosureSEC source: 0001127602-15-024175 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,934 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 40,621 RSUs which vest in two equal installments of 13,540 on 8/1/2016 and 8/1/2017 and one installment of 13,541 on 8/1/2018; and 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1/340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 782 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:07 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004139 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,537 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 54,161 RSUs which vest in three equal installments of 13,540 on 8/1/2015, 8/1/2016 and 8/1/2017 and one installment of 13,541 on 8/1/2018; and 3,940 RSUs whicdh vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1/340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 436 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 01, 2014 Filed Aug 5, 2014 20:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 54,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-024795 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,161 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three equal installments of 13,540 on 8/1/2015, 8/1/2016 and 8/1/2017 and one installment of 13,541 on 8/1/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.